Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1β, -6, -8 and -10
Corresponding Author
A. UYS phd, clinical trial coordinator
The Medical Oncology Centre of Rosebank, Johannesburg,
Almarie Uys, The Medical Oncology Centre of Rosebank, Johannesburg, South Africa (e-mail: [email protected]).Search for more papers by this authorB.L. RAPOPORT md, mmed, director and physician in charge
The Medical Oncology Centre of Rosebank, Johannesburg,
Search for more papers by this authorH. FICKL msc, senior medical scientist
Medical Research Council Unit for Inflammation and Immunity, Department of Immunology, Faculty of Health Sciences, University of Pretoria and Tshwane Academic, Division of the National Health Laboratory Services, Pretoria, South Africa
Search for more papers by this authorP.W.A. MEYER mtech, laboratory manager
Medical Research Council Unit for Inflammation and Immunity, Department of Immunology, Faculty of Health Sciences, University of Pretoria and Tshwane Academic, Division of the National Health Laboratory Services, Pretoria, South Africa
Search for more papers by this authorR. ANDERSON phd, head of department
Medical Research Council Unit for Inflammation and Immunity, Department of Immunology, Faculty of Health Sciences, University of Pretoria and Tshwane Academic, Division of the National Health Laboratory Services, Pretoria, South Africa
Search for more papers by this authorCorresponding Author
A. UYS phd, clinical trial coordinator
The Medical Oncology Centre of Rosebank, Johannesburg,
Almarie Uys, The Medical Oncology Centre of Rosebank, Johannesburg, South Africa (e-mail: [email protected]).Search for more papers by this authorB.L. RAPOPORT md, mmed, director and physician in charge
The Medical Oncology Centre of Rosebank, Johannesburg,
Search for more papers by this authorH. FICKL msc, senior medical scientist
Medical Research Council Unit for Inflammation and Immunity, Department of Immunology, Faculty of Health Sciences, University of Pretoria and Tshwane Academic, Division of the National Health Laboratory Services, Pretoria, South Africa
Search for more papers by this authorP.W.A. MEYER mtech, laboratory manager
Medical Research Council Unit for Inflammation and Immunity, Department of Immunology, Faculty of Health Sciences, University of Pretoria and Tshwane Academic, Division of the National Health Laboratory Services, Pretoria, South Africa
Search for more papers by this authorR. ANDERSON phd, head of department
Medical Research Council Unit for Inflammation and Immunity, Department of Immunology, Faculty of Health Sciences, University of Pretoria and Tshwane Academic, Division of the National Health Laboratory Services, Pretoria, South Africa
Search for more papers by this authorAbstract
The primary objective of the study was to compare the predictive potential of procalcitonin (PCT), C-reactive protein (CRP), serum amyloid A (SAA), and interleukin (IL)-1β, IL-6, IL-8, and IL-10, with that of the Multinational Association of Supportive Care in Cancer (MASCC) risk-index score in cancer patients on presentation with chemotherapy-induced febrile neutropenia (FN). Seventy-eight consecutive FN episodes in 63 patients were included, and MASCC scores, as well as concentrations of CRP, SAA, PCT, and IL-1β, IL-6, IL-8 and IL-10, and haematological parameters were determined on presentation, 72 h later and at outcome. Multivariate analysis of data revealed the MASCC score, but none of the laboratory parameters, to be an accurate, independent variable (P < 0.0001) for prediction of resolution with or without complications and death. Of the various laboratory parameters, PCT had the strongest association with the MASCC score (r = −0.51; P < 0.0001). In cancer patients who present with FN, the MASCC risk-index score is a useful predictor of outcome, while measurement of PCT, CRP, SAA, or IL-1β, IL-6, IL-8 and IL-10, is of limited value.
REFERENCES
- Abrahamsson J., Påhlman M. & Mellander L. (1997) Interleukin 6, but not tumour necrosis factor-α, is a good predictor of severe infection in febrile neutropenic and non-neutropenic children with malignancy. Acta Paediatrica 86, 1059–1964.
- Bernard L., Ferrière F., Casassus P., Malas F., Leveque S., Guillevin L. & Lortholary O. (1998) Procalcitonin as an early marker of bacterial infection in severely neutropenic febrile adults. Clinical Infectious Diseases 27, 914–915.
- Boussekey N., Leroy O., Georges H., Devos P., D’Escrivan T. & Guery B. (2005) Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection 33, 257–263.
- Chan Y.L., Tseng C.P., Tsay P.K., Chang S.S., Chiu T.F. & Chen J.C. (2004) Procalcitonin as a marker of bacterial infection in the emergency department: an observational study. Critical Care 8, R12–R20.
- Chirouze C., Schuhmacher H., Rabaud C., Gill H., Khayat N., Estavoyer J., May T. & Hoen B. (2002) Low serum procalcitonin level accurately predicts the absence of bacteraemia in adult patients with acute fever. Clinical Infectious Diseases 15, 156–161.
- De Bont E.S., Vellenga E., Swaanenburg J.C., Fidler V., Visser-van Brummen P.J. & Kamps W.A. (1999) Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. British Journal of Haematology 107, 375–380.
- De Bont E.S.J.M., Vellenga E. & Swaanenburg J. (2000) Procalcitonin: a diagnostic marker of bacterial infection in neutropenic cancer patients with fever. Infection 28, 398–400.
- Engel A., Mack E., Kern P. & Kern W.V. (1998) An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, Gram-negative bacteraemia and complicated infection in neutropenic cancer patients. Infection 26, 213–221.
- Engel A., Steinbach G., Kern P. & Kern W.V. (1999) Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scandinavian Journal of Infectious Diseases 31, 185–189.
- Engervall P., Andersson B. & Björkholm M. (1995a) Clinical significance of serum cytokine patterns during start of fever in patients with neutropenia. British Journal of Haematology 91, 838–845.
- Engervall P., Granström M., Andersson B. & Björkholm M. (1995b) Monitoring of endotoxin, interleukin-6 and C-reactive protein serum concentrations in neutropenic patients with fever. European Journal of Haematology 54, 226–234.
- Feld R. (2000) Multinational cooperation in trials and guidelines dealing with febrile neutropenia. International Journal of Antimicrobial Agents 16, 185–187.
- Ffmeaux T. & Pugin T. (2002) Role of interleukin-10 in the intracellular sequestration of human leucocyte antigen-DR in monocytes during septic shock. American Journal of Respiratory and Critical Care Medicine 166, 1475–1483.
- Fleischhack G., Kambeck I., Cipic D., Hasan C. & Bode U. (2000) Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. British Journal of Haematology 111, 1093–1102.
- Giamarellou H., Giamarellos-Bourboulis E.J., Repoussis P., Galani L., Anagnostopoulos N., Grecka P., Lubos A., Aoun M., Athanassiou K., Bou E., Devigili E., Krcmery V., Menichetti F., Panaretou E., Papageorgiou E. & Plachouras D. (2004) Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clinical Microbiology and Infection 10, 628–633.
- Giamarellos-Bourboulis E.J., Grecka P., Poulakou G., Poulakou G., Anargyrou K., Katsilambros N. & Giamarellou H. (2001) Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clinical Infectious Diseases 32, 1718–1725.
- Gibot S., Cravoisy A., Levy B., Bene M., Faure G. & Bollaert P. (2004) Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. New England Journal of Medicine 350, 451–458.
- Harbarth S., Holeckova K., Froidevaux C., Pittet D., Ricou B., Grau G.E., Vadas L., Pugin J. and the Geneva Sepsis Network (2001) Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. American Journal of Respiratory and Critical Care Medicine 164, 396–402.
- Jimeno A., Garcia-Velasco A., Del Val O., Gonzalez-Billalabeitia E., Hernando S., Hernandez R., Sanchez-Munoz A., Lopez-Martin A., Duran Robles L., Cortes-Funes H. & Paz-Ares L. (2004) Assessment of procalcitonin as a diagnostic marker in patients with solid tumors and febrile neutropenia. Cancer 100, 2462–2469.
- Karan M.A. (2002) Predictive value of higher plasma interleukin-6 levels in patients with febrile neutropenia. Archives of Medical Research 33, 557–561.
- Kern W.V., Heiss M. & Steinbach G. (2001) Prediction of Gram-negative bacteraemia in patients with cancer and febrile neutropenia by means of interleukin-8 levels in serum: targeting empirical monotherapy versus combination therapy. Clinical Infectious Diseases 32, 832–835.
- Klastersky J., Paesmans M., Rubenstein E.B., Boyer M., Elting L., Feld R., Gallagher J., Herrstedt J., Rapoport B., Rolston K. & Talcott J.A. (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Journal of Clinical Oncology 18, 3038–3051.
- Lehrnbecher T., Venzon D., De Haas M., Chanock S.J. & Kuhl J. (1999) Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fcγ receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clinical Infectious Diseases 29, 414–419.
- Liaudat S., Dayer E., Praz G., Bille J. & Troillet N. (2001) Usefulness of procalcitonin serum level for the diagnosis of bacteraemia. European Journal of Clinical Microbiology and Infectious Diseases 20, 524–527.
- Meisner M. (2005) Biomarkers of sepsis: clinically useful? Current Opinion in Critical Care 11, 473–480.
- Penel N., Fournier C., Clisant S. & N’Guyen M. (2004) Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever. Support Care Cancer 12, 593–598.
- Persson L., Engervall P., Magnuson A., Vikerfors T., Soderquist B., Hannson L.O. & Tidefelt U. (2004) Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scandinavian Journal of Infectious Diseases 36, 365–337.
- Rackoff W.R., Gonin R., Robinson C. & Kreissman S.G. (1996) Predicting the risk of bacteraemia in children with fever and neutropenia. Journal of Clinical Oncology 14, 919–924.
- Ruokonen E., Nousiainen T., Pulkki K. & Takala J. (1999) Procalcitonin concentrations in patients with neutropenic fever. European Journal of Clinical Microbiology and Infectious Disease 18, 283–285.
- Sauer M., Tiede K., Volland R. & Zintl F. (2000) Procalcitonin and C-reactive protein: comparison of two markers for sepsis syndrome in severely immunocompromised children after bone marrow transplantation. Clin Peadiatr 212, 10–15.
- Schönbohn H., Schuler M., Kolbe K., Peschel C., Huber C., Bemb W. & Aulitzky W.E. (1995) Plasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF and IL1-RA during febrile neutropenia: results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia. Annals of Hematology 71, 161–168.
- Südhoff T., Giagounidis A. & Karthaus M. (2000) Evaluation of neutropenic fever: value of serum and plasma parameters in clinical practice. Chemotherapy 46, 77–85.
- Svaldi M., Hirber J., Lanthaler A.I., Mayr O., Faes S., Peer E. & Mitterer M. (2001) Procalcitonin-reduced sensitivity and specificity in heavily leukopenic and immunosuppressed patients. British Journal of Haematology 115, 53–57.
- Uys A., Rapoport B.L. & Anderson R. (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer risk-index score. Supportive Care in Cancer 12, 555–560.
- Viscoli C. & Castagnola E. (2002) Treatment of febrile neutropenia: what is new? Current Opinion in Infectious Diseases 15, 377–382.
- Von Lilienfeld-Toal M., Dietrich M.P., Glasmacher A., Lehman L., Breig P., Hahn C., Schmidt-Wolf I.G., Marklein G., Schroeder S. & Stuber F. (2004) Markers of bacteraemia in febrile neutropenic patients with haematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. European Journal of Clinical Microbiology and Infectious Diseases 23, 539–544.
